SCHEMBL6446526

SCHEMBL6446526

CS(=O)(=O)OCCC#CC1CCN(S(=O)(=O)c2ccc(C(F)(F)F)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
GAA P10253 3/20 0.47
ALDH1A1 P00352 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.43
TRPV4 Q9HBA0 3/20 0.43
EPHX2 P34913 2/20 0.43
HSD11B1 P28845 1/20 0.42
CCR6 P51684 2/20 0.41
EPHX1 P07099 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TSHR P16473 1/20 0.41
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
USP2 O75604 1/20 0.40
POLB P06746 1/20 0.40
HTT P42858 1/20 0.40
MAPK10 P53779 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6451272 0.89 MEN1 (0.51) MEN1KMT2AGAAALDH1A1L3MBTL1
SCHEMBL6455036 0.81 MEN1 (0.49) MEN1KMT2AGAAALDH1A1L3MBTL1
SCHEMBL6449475 0.79 TRPV4 (0.47) MEN1KMT2AGAAALDH1A1L3MBTL1
SCHEMBL6446550 0.79 TRPV4 (0.48) MEN1KMT2AGAAALDH1A1TRPV4
SCHEMBL6447839 0.78 TRPV4 (0.46) MEN1KMT2AGAAALDH1A1TRPV4
SCHEMBL6446567 0.77 TRPV4 (0.48) MEN1KMT2AGAAALDH1A1TRPV4
SCHEMBL6449496 0.77 LSS (0.48) MEN1KMT2AGAAALDH1A1TRPV4
SCHEMBL6450254 0.76 TRPV4 (0.51) MEN1KMT2AGAAALDH1A1TRPV4
SCHEMBL6446562 0.75 LSS (0.52) MEN1KMT2AGAAALDH1A1TRPV4
SCHEMBL6447874 0.75 LSS (0.51) MEN1KMT2AGAAALDH1A1TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6964974-B2 2,3-oxidosqualene-lanosterol cyclase inhibitors HOFFMANN-LA ROCHE INC. (US) 2005-11-15 US disclosed
EP-1317432-A1 PIPERIDINE DERIVATIVES FOR USE AS 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2003-06-11 EP disclosed
US-20020068753-A1 2,3-oxidosqualene-lanosterol cyclase inhibitors HOFFMANN-LA ROCHE INC. 2002-06-06 US disclosed
WO-2002020483-A1 PIPERIDINE DERIVATIVES FOR USE 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2002-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068753-A1 2,3-oxidosqualene-lanosterol cyclase inhibitors CYP51A1, LSS, CYP46A1 MEN1 1040/4885KMT2A 3743/4885GAA 591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.